The fact that they have declining sales with a GLP-1 is laughable.

---

Hey all, Not a buy/sell call — sharing a setup I’m watching because the risk/reward is changing with time-boxed catalysts and shorts are still in. 1. Structure first: why this even matters • Ticker: $ALT • Float: relatively tight vs. daily volume on news days • Shorts: still meaningful — which = fuel if they’re wrong on timing • Catalyst window: company already put dates in the public domain (earnings + liver data), so we actually know when the next info hits • Sector narrative: obesity/MASH names are back in rotation — attention helps. When you get (shorts) + (attention sector) + (dated catalyst) you don’t need everyone to pile in — you just need enough volume ahead of the date to make shorts uncomfortable. 2. What the crowd is likely to react to • It’s a data/name stock, not a zombie shell. • The drug (pemvidutide) has real 24-week data in MASH/weight already out there. • Management already said they’re moving toward 48-week data + FDA conversation. That’s a story people understand: “data → talk to FDA → Phase 3”. • That’s easy for Reddit/FinTwit to narrate. So you’ve got a story people can repeat in 1–2 sentences — that’s underrated. 3. Why shorts stay in (and why that’s a tell) Shorts love these because: 1. It’s biotech (binary outcomes, dilution risk). 2. Phase 3 in MASH is expensive → “they’ll raise”. 3. Data not 100% de-risked → “I can stay short until the readout”. That’s fine — but when the calendar gets close and volume wakes up, shorts have to rethink sizing. That rethink = potential upside pressure. 4. What to watch (this is the important part) • Volume spike before the event – if average daily volume suddenly 2–3x’s without bad news, someone is positioning. • Option chain getting busy – especially if OTM calls pick up in the same expiry as the catalyst. • Tape around pre-market/last hour – if it keeps getting bought back after dips, that’s someone absorbing. • Company IR drops slides/posters – gives fresh material for socials to circulate. If 2 or more of those happen at the same time, shorts don’t have a free ride anymore. 5. Possible headlines the market can latch onto This is how I expect people to talk about it (this is psychology): • “Small float MASH name with real data coming” • “Shorts still in before the 48-week readout” • “Next GLP-1/MASH sympathy runner?” • “Call today – management will have to guide” You don’t need them to be true in the strongest sense — you just need them to be plausible based on public info. 6. Risks (read these, seriously) • If the company pushes the timeline → setup weakens. • If they guide to a big, near-term raise → shorts relax. • If the 48-week data underwhelms → it unwinds fast (biotech). • This is not BYND — that was a perfect storm of short interest, meme ETF flows, and viral clips. Don’t assume repeat.

---

Altimmune ($ALT) — Near-term catalysts in MASH; 48-week readout and FDA meeting on deck Altimmune’s dual GLP-1/glucagon agonist pemvidutide has positive 24-week Phase 2b data in MASH with weight loss and strong NIT signals. Near-term catalysts include: (1) Q3 results + business update on 6 Nov 2025, (2) AASLD late-breaking oral/poster the same week, and (3) 48-week IMPACT data in Q4 2025, followed by an End-of-Phase-2 (EOP2) FDA meeting targeted for Q4 2025. Cash was $183.1m (30 Jun 2025). Watch short-interest dynamics and the Phase 3 path in MASH.  Investment thesis (biotech-focused, medium risk) Clinical signal: At 24 weeks, pemvidutide met the primary endpoint (MASH resolution without fibrosis worsening) with up to 59.1% response in ITT analysis, alongside meaningful weight loss and improvements on NITs (e.g., ELF, VCTE, cT1). These markers support anti-inflammatory and anti-fibrotic activity pending biopsy-based confirmation at 48 weeks.   What’s different: Company secured late-breaking slots at AASLD 2025 (oral + poster) for 24-week data, a credibility signal in liver circles, and guides to 48-week IMPACT data in Q4 2025 (weight, NITs, safety).   Execution adds up: Altimmune scheduled Q3 results and business update on 6 Nov 2025; management recently strengthened clinical leadership by appointing Christophe Arbet-Engels, M.D., PhD as CMO to steer Phase 3 in MASH.   Near-term catalysts (dated) 6 Nov 2025 (Thu): Q3 results & business update call (watch for Phase 3 colour, 48-week timing, cash runway commentary).   7–11 Nov 2025: AASLD The Liver Meeting late-breaking oral + poster on 24-week IMPACT data; expect slides/posters on the IR site.   Q4 2025: 48-week IMPACT readout (weight loss trajectory, NITs, safety; biopsy subset/AI fibrosis analyses may be discussed). Company also targets EOP2 FDA meeting in Q4 2025 to align Phase 3.   Balance sheet & ownership watch-outs Cash: $183.1m as of 30 June 2025; net loss $22.1m for Q2. Provides a cushion into 2026, but Phase 3 will be capital-intensive—monitor financing overhang.   Short interest: As of 15 Oct 2025, reported short interest around 21.5m shares (down vs end-Sept). Any data surprise can move borrow/price quickly.   Pipeline context (beyond MASH) Obesity: EOP2 meeting for obesity completed previously; programme remains a strategic option post-MASH clarity.   Adjacencies (liver/behavioural): RECLAIM (AUD) and RESTORE (ALD) Phase 2 trials initiated in 2025 - optionality if MASH succeeds.   Key risks Biopsy-level uncertainty: 24-week signals are strong, but regulators care about biopsy endpoints and longer-term safety; 48-week data are the inflection.   Funding/di­lution: Advancing to MASH Phase 3 likely requires more capital. Watch the Q3 call and subsequent filings.   Competitive landscape: GLP-1s and emerging MASH agents are crowded fields; differentiation on efficacy/tolerability, fibrosis impact, and combo potential will matter (AASLD discussion will help).

---

Lol I know more men on GLP then women.

---

Is the price cap going to reduce glp revenu by 90%

---

buy [HYFT.us](http://HYFT.us) , for GLP-1 !

---